GlaxoSmithKline UK

not be usedavoided in patients with skeletal muscle myopathies, e.g. Duchenne muscular dystrophy since its administration may be associated with rigidity, malignant hyperthermia, ventricular dysrhythmias and cardiac arrest secondary to acute rhabdomyolysis with hyperkalaemia, myoglobinaemia, cardiac arrest, and post-operative respiratory depression."

Section 4.4 - The fifth paragraph from the end of this section has been updated to read:

"Caution should be exercised when using suxamethonium in children, since paediatric patients are more likely to have an undiagnosed myopathy or an unknown predisposition to malignant hyperthermia

and rhabdomyolysis, which places them at increased risk of serious adverse events following suxamethonium (see section 4.3 Contraindications and section 4.8 Adverse Reactions)."

Section 4.8 - The first paragraph has been updated to read:

"Adverse reactions are listed below by system organ class

and frequency. Estimated frequencies were determined from published data. Frequencies are defined as follows: very common (=1/10); common (=1/100 and <1/10), uncommon (=1/1,000 and <1/100); rare (=1/10,000 and <1/1,000); very rare (<1/10,000)."

also, Musculoskeletal and connective tissue disorders and General disorders have been updated as follows:

"Musculoskeletal and connective tissue disorders

Very common Muscle fasciculation, post-operative muscle pains (Please refer to section 4.4 Special Warnings and Precautions for Use).

Common Myoglobinaemia

#, myoglobinuria#.

Rare Trismus

# Rhabdomyolysis has also been reported (see section 4.3 Contraindications and section 4.4 Special Warnings and Precautions for Use)

General disorders and administration site conditions
Very rare Malignant hHyperthermia (Please refer to section 4.4 Special Warnings and Precautions for Use)."

Section 10 - Change date to: